Alpha-1 Antitrypsin Deficiency Clinical Landscape Report 2026: Trials, Readouts and White Space
Turn fragmented clinical intelligence into a decision-ready landscape. This report was assembled with PatSnap MCP Servers for Clinical Trials, Drug & Asset, and Company & Deal Intelligence. Explore the PatSnap MCP Marketplace to reproduce the workflow in your own AI research stack.
Data snapshot: 16 July 2026. This report is a strategic research view, not medical advice. Trial status and timing can change; confirm records before making development or investment decisions.
Executive view
Alpha-1 Antitrypsin Deficiency remains an active clinical development field. One-time and precision therapies are raising the efficacy ceiling, but durability, manufacturing, small-population evidence and long-term safety remain decisive constraints. The PatSnap evidence set used here contains 32 matched trial records and 36 indexed result records before the decision-focused sample below was selected.
How PatSnap MCP built this report
The workflow used Clinical Trials MCP search to define the landscape, then clinical_trial_fetch to retrieve trial design, phase, status, sponsor, geography, endpoints and timing. It separately called clinical_trial_result_fetch for indexed readouts. Drug & Asset drug_fetch supplied target and global development status, while Company & Deal Intelligence organization_fetch supplied sponsor context. This keeps trial-, asset- and company-level claims distinct and traceable.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Expected readout |
|---|---|---|---|---|---|---|
| NCT07639996 | Intervention not normalized | Not Applicable; Not yet recruiting | Assiut University | Geography not listed | Search for serum-based disease biomarkers and the associated molecular pathways (Eight months of performing serum proteomics to identify biomarkers that…) | 2027-09-30 |
| NCT07555483 | Alpha1-proteinase inhibitor(Grifols SA) | Phase 3; Recruiting | Grifols Therapeutics LLC | Sweden, Netherlands, United States, Ireland, Poland +4 more | Steady-state AUC of alpha1-PI over the weekly dosing interval (from 0 to 7 days) (AUC0-7 days) in the IV Treatment Period 1 and in the SC Treatment Period 2 for both dose levels (Week 1 to Week 16) | 2027-09-30 |
| NCT07431112 | AIR-001 (AIRNA) | Phase 1; Recruiting | Airna, Inc. | United Kingdom, United States, Australia | Number of participants with treatment-emergent adverse events (TEAEs) (Up to Day 169); Incidence of laboratory abnormalities and shifts from baseline, including hematology, chemistry, coagulation, and urinalysis parameters (Baseline through up to Day 169) | 2028-11-01 |
| NCT07326592 | Alpha-1-Proteinase Inhibitor (Human)(CSL Behring) | Phase 4; Not yet recruiting | CSL Behring LLC | Geography not listed | Annual rate of change in adjusted lung density (From Baseline to Month 36) | 2033-09-15 |
The table is designed for competitive decisions: endpoint selection, geographic reach and readout timing appear beside phase and sponsor. Phase alone does not reveal evidence maturity; a small study may answer a near-term biomarker question while a large pivotal program can leave a multi-year readout gap.
What indexed results say
- A Phase 1, Randomized, Double-blind, Placebo-controlled, Safety, Tolerability, and Pharmacokinetic Study of Single Ascending Doses and Multiple Doses of WVE-006 in Healthy Participants (Phase 1): the indexed record reports The Proportion of Participants With Adverse Events = 5 Participants; -; -.
- A Phase 2, Open-label Study Evaluating Efficacy and Safety of VX-864 in Subjects With Alpha-1 Antitrypsin Deficiency Who Have the PiZZ Genotype, Over 48 Weeks (Phase 2): the indexed record reports Participants with TEAEs = 4 Participants; -; Participants with TEAEs = 10 Participants.
- Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency (Phase 1/2): the indexed record reports AE = All adverse events (AEs) were mild to moderate in intensity. No SAEs or discontinuations.; AE = All adverse events (AEs) were mild to moderate in intensity. No SAEs or discontinuations.; AE = All adverse events (AEs) were mild to moderate in intensity. No SAEs or discontinuations..
Cross-trial comparisons require caution. Population, prior therapy, baseline risk, endpoint definition, follow-up and analysis set can all change the apparent signal. The strategic value lies in identifying what each readout resolves—and which uncertainty remains.
Build a living clinical map: connect to PatSnap MCP Servers and combine trial design, result, asset and organization records without manually reconciling separate databases.
Asset and sponsor context
PatSnap Drug & Asset records add mechanism and global development status for the sampled programs, including Alpha1-proteinase inhibitor(Grifols SA) (Approved; A1AT), AIR-001 (AIRNA) (Phase 1; A1AT), Alpha-1-Proteinase Inhibitor (Human)(CSL Behring) (Approved; ELA2). Company & Deal Intelligence records identify sponsor context for Assiut University, Grifols Therapeutics LLC, Airna, Inc., CSL Behring LLC. Together, those layers show whether a study sits inside a scaled portfolio, an emerging specialist strategy or an academic development path.
Where the white space is
- Natural-history-aligned endpoints that remain interpretable in small heterogeneous cohorts.
- Long-term registries for durability, immunogenicity and delayed safety signals.
- Redosing, rescue and treatment-sequencing strategies after incomplete response.
- Access models that address diagnosis, manufacturing and global delivery.
Strategic implications
For sponsors, differentiation is more credible when the evidence package resolves a known decision gap: an active comparator, a better-defined responder population, a safer or easier delivery model, a clinically meaningful outcome, or a defensible sequencing strategy. Business-development teams can use the same landscape to separate crowded mechanisms from differentiated evidence architectures. Investors should track endpoint maturity and operational feasibility alongside nominal phase.
What to monitor next
Track status changes, protocol amendments, primary-completion dates, newly indexed results, ownership changes and multinational expansion. Re-run the MCP queries on a schedule and compare deltas. Pay particular attention when a program moves from a surrogate endpoint to a clinical outcome or when a specialist sponsor adds a scaled development partner.
Bottom line
Alpha-1 Antitrypsin Deficiency has meaningful clinical activity and equally meaningful evidence gaps. A useful landscape connects trial design, results, mechanism and sponsor rather than listing studies in isolation.
Ready to reproduce this analysis? Explore PatSnap MCP Servers and use Clinical Trials, Drug & Asset, and Company & Deal Intelligence as structured building blocks for monitoring and SEO-ready clinical reports.
